Published online before print August 7, 2006, doi: 10.1161/CIRCULATIONAHA.106.177321
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:1083-1087.)
© 2006 American Heart Association, Inc.
AHA Science Advisory |
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation
 |
Abstract |
|---|
 Top Abstract References |
|---|
Chronic kidney disease (CKD) occurs commonly in patients with cardiovascular disease. In addition, CKD is a risk factor for the development and progression of cardiovascular disease. In this advisory, we present recommendations for the detection of CKD in patients with cardiovascular disease. CKD can be reliably detected with the combined use of the Modification of Diet in Renal Disease equation to estimate glomerular filtration rate and a sensitive test to detect microalbuminuria. All patients with cardiovascular disease should be screened for evidence of kidney disease with these two determinations.
Key Words: AHA Scientific Statements • chronic kidney disease • albuminuria • risk factors
Recommendations
- Class I
- The Modification of Diet in Renal Disease (MDRD) equation should be used to estimate glomerular filtration rate in adult patients with cardiovascular disease. Values <60 mL/min per 1.73 square meters body surface area should be regarded as abnormal. (Level of Evidence: B)
- Class IIa
- The albumin-to-creatinine ratio should be used to screen for the presence of kidney damage in adult patients with cardiovascular disease. Values >30 mg albumin per 1 g creatinine should be regarded as abnormal. (Level of Evidence: B)
- All adult patients with cardiovascular disease should be screened for evidence of kidney disease with determinations of estimated glomerular filtration rate using the MDRD equation and albumin-to-creatinine ratio. (Level of Evidence: C)
- The Modification of Diet in Renal Disease (MDRD) equation should be used to estimate glomerular filtration rate in adult patients with cardiovascular disease. Values <60 mL/min per 1.73 square meters body surface area should be regarded as abnormal. (Level of Evidence: B)
It is estimated that up to 11% of adults in the United States have chronic kidney disease (CKD),1 and the prevalence of CKD is even higher among patients with cardiovascular disease.2 Additionally, CKD is a major and serious risk factor for cardiovascular disease.2 Death from cardiovascular disease is 10 to 30 times higher in dialysis patients than in the general population. Recent studies have confirmed that even early CKD constitutes a significant risk factor for cardiovascular events and death.3,4 In addition, CKD is a risk factor for recurrent cardiovascular events,5 and proper management of cardiovascular disease is different and more complex in patients with CKD.6 Finally, both the frequency of cardiovascular complications and the progression of CKD can be ameliorated in these patients by appropriate intervention. For all these reasons, healthcare providers should evaluate their patients for the presence of CKD as part of preventive care and treatment strategies.
CKD is defined as structural or functional abnormalities of the kidney that persist for at least 3 months and are manifested by either kidney damage (most frequently detected as persistent albuminuria; >30 mg albumin/g creatinine) or a decreased glomerular filtration rate (GFR) (<60 mL/min per 1.73 m2). Because techniques commonly used to estimate renal function often fail to detect patients with mild to moderate reduction in GFR and because screening for albuminuria is not consistently performed, CKD in many patients remains unidentified. Because a clinically useful method of accurately detecting CKD in patients is needed, this advisory will address currently available methods and make recommendations about the most appropriate screening tests for CKD.
The most accurate method to determine kidney function is a formal GFR measurement with iothalamate or similar markers. Such time-consuming tests are expensive, generally unsuitable for clinical practice, available in only a few centers, and certainly not cost-effective for CKD screening. Creatinine is a useful endogenous marker of renal filtration or GFR, but there are problems with the routine use of serum creatinine to estimate GFR. Inference of GFR from the serum creatinine level alone is complicated by the differing rates of creatinine production between persons, mainly because of variations in muscle mass. Women and the elderly often have deceptively low serum creatinine levels, despite substantial reductions in GFR. The inverse, nonlinear relation between serum creatinine level and GFR also clouds interpretation; healthcare providers often misinterpret small increases in creatinine as clinically insignificant. Currently, more suitable serum indicators of GFR are not available, although one possible exception to this is cystatin C.
Cystatin C is a serine protease inhibitor released at a relatively constant rate from all cells and is freely filtered by the glomerulus. Several studies have suggested that it may approximate GFR better than creatinine,7–9 and a recent report has found that cystatin C levels better predict the development of congestive heart failure in elderly patients than do serum creatinine values.10 However, cystatin C production may not remain completely constant, and factors other than kidney function may affect cystatin C levels, such as age, male sex, weight, height, cigarette smoking, serum C-reactive protein levels, steroid therapy, and rheumatoid arthritis.11,12 Therefore, it is not certain that cystatin C has sufficient specificity to serve as a reliable indicator of GFR.
Traditionally, calculation of creatinine clearance from timed urine collections has been used for estimation of GFR. However, these timed urine collections are cumbersome and fraught with error, largely as a result of inaccurate urine collection.
Given the lack of accuracy of these methods, a more suitable screening test for GFR is needed. Fortunately, several validated estimation equations for GFR that use easily obtained clinical data and laboratory test results are available. These methods allow healthcare providers to diagnose CKD with greater accuracy. This advisory will describe these methods and their applicability to patients with cardiovascular disease.
Over the past decade, equations that estimate GFR on the basis of serum creatinine concentration and other easily obtainable patient data have been developed and validated. The widely used Cockcroft-Gault method uses serum creatinine, gender, age, and ideal weight.13 However, weight measurements or estimations make calculation and reporting of Cockcroft-Gault results by laboratories problematic.
Other formulas have been validated that use data that are readily available to laboratories.14–16 The formula developed from the Modification of Diet in Renal Disease (MDRD) study14,15 is currently the best validated method to estimate GFR for adults in the typical office setting. There are 2 forms of this equation (Table 1). The original equation requires several laboratory tests in addition to the serum creatinine value, whereas the abbreviated MDRD study equation requires only demographic data plus the serum creatinine value. The abbreviated version appears to produce essentially similar results and is simpler.17,18 It is important to note that GFR values derived from either form of the MDRD study equation can be automatically generated and placed in laboratory reports of any patient, because the age and gender information needed to make the calculation is generally included in the database on each patient. Because race is often not included in such databases, automatic reporting will include a comment asking the practitioner to multiply the calculated GFR by 1.21 for black patients.
|
Online calculators for the MDRD GFR equation are available from the National Kidney Foundation at www.kidney.org and from the National Kidney Disease Education Program (NKDEP) of the National Institutes of Health at www.nkdep.nih.gov. The National Kidney Foundation and the American Society of Nephrology have joined with the NKDEP to educate healthcare providers about the need to routinely screen for CKD. In addition, these groups are encouraging laboratories to report estimated GFR using the MDRD formula along with serum creatinine to improve early detection of CKD.19
Although both forms of the MDRD study equation have been validated by other research groups for patients with significant reduction in GFR, their accuracy is reduced in persons with normal or only slightly diminished renal function. As screening tools, they can overestimate the number of patients with CKD,17,18,20 and their accuracy in patients with cardiovascular disease has not been well substantiated. However, a study of patients with left ventricular dysfunction showed that a GFR <60 mL/min per 1.73 m2, calculated by the MDRD study equation, remained an independent risk factor for death,21 which suggests that the predictive value of the test was high. On balance, therefore, the MDRD study equation appears to accurately detect CKD in heart failure patients, including those with GFRs <60 mL/min per 1.73 m2, and is likely to be applicable to patients with other cardiovascular diseases.
Albuminuria (>30 mg urinary albumin excretion per 24 hours) is associated with an increased risk for cardiovascular disease.2,4 Spot urinary values >30 mg albumin/g creatinine are abnormal; repeated elevations of the urinary albumin-to-creatinine ratio over several months confirm increased cardiovascular risk and suggest the presence of CKD (Table 2). It should be noted that increased albuminuria may also reflect the presence of generalized endothelial dysfunction.22,23 However, either condition is associated with increased cardiovascular risk. Therefore, screening for albuminuria should be included in the assessment of all patients. Urine albumin excretion of <300 mg/g creatinine is not reliably detectable with routine dipstick methods, so screening is best accomplished by determining the albumin-to-creatinine ratio on a spot urine specimen. Patients should be tested only when in stable condition without other acute complications, such as exacerbations of congestive heart failure, volume overload, and urinary tract infections, because these and other acute alterations are associated with transient increases in albumin excretion.24 Finally, the sensitivity of this test may be reduced in patients who are already on angiotensin receptor blockade or angiotensin-converting enzyme inhibitor medications. Nonetheless, persistent albuminuria in that setting would likely reflect the presence of CKD. These urinary measurements have also been recommended as the standard of care by the National Kidney Foundation,25–27 the American Diabetes Association,24 and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure28 to screen for kidney disease.
|
Combined screening for microalbuminuria and estimation of GFR with the MDRD study equation are recommended for all adult patients with cardiovascular disease, including those with coronary artery disease or congestive heart failure as well as those with risk factors for CKD such as diabetes and hypertension, which are also risk factors for cardiovascular disease. Repeat screening at 3 months should be performed if either test is positive. If either test remains positive over at least a 3-month period, the patient should be considered to have CKD, and appropriate evaluation as to the cause of the CKD and appropriate treatment should be undertaken as noted in several published guidelines.25–28
|
Acknowledgments |
|---|
Disclosures
|
|
|
Footnotes |
|---|
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
This advisory was approved by the American Heart Association Science Advisory and Coordinating Committee on June 28, 2006. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0372. To purchase additional reprints: Up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kelle.ramsay@wolterskluwer.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://www.americanheart.org/presenter.jhtml?identifier=3023366.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the "Permission Request Form" appears on the right side of the page.
|
References |
|---|
|
TopAbstractReferences |
|---|
1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1–12.[Medline] [Order article via Infotrieve]
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154–2169.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction [published comments in ACP J Club. 2005;142:51, N Engl J Med. 2004;351:1344–1346, and N Engl J Med. 2005;352:199–200; author reply 199–200]. N Engl J Med. 2004; 351: 1285–1295.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published comments in ACP J Club. 2005;142:50–51, N Engl J Med. 2004;351:1344–1346, and N Engl J Med. 2005;352:199–200, author reply 199–200]. N Engl J Med. 2004; 351: 1296–1305.
5. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004; 44: 198–206.[Medline] [Order article via Infotrieve]
6. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol. 2004; 44: 1343–1353.
7. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment [published comments in Am J Kidney Dis. 2000;36:205–207, Am J Kidney Dis. 2001;37:448–451]. Am J Kidney Dis. 2000; 36: 29–34.[Medline] [Order article via Infotrieve]
8. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001; 37: 79–83.[Medline] [Order article via Infotrieve]
9. Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003; 18: 2024–2031.
10. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG; Cardiovascular Health Study. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005; 142: 497–505.
11. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement [published comment in Kidney Int. 2005;67:777–778; author reply 778–779]. Kidney Int. 2004; 65: 1416–1421.[CrossRef][Medline] [Order article via Infotrieve]
12. Levin A. Cystatin C, serum creatinine, and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk [published comment in Ann Intern Med. 2005;142:497–505]. Ann Intern Med. 2005; 142: 586–588.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.[Medline] [Order article via Infotrieve]
14. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group [published comments in ACP J Club. 1994;121(suppl 2):46, N Engl J Med. 1994;331:405; author reply 405–406, N Engl J Med. 1994;330:929–930]. N Engl J Med. 1994; 330: 877–884.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group [published comments in Ann Intern Med. 1999;131:629–630; author reply 630, Ann Intern Med. 2004;140:934; author reply 934–935]. Ann Intern Med. 1999; 130: 461–470.
16. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, Krumholz HM. Serum urea nitrogen, creatinine, and estimators of renal function mortality in older patients with cardiovascular disease. Arch Intern Med. 2006; 166: 1134–1142.
17. Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000; 11: 155A.
18. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease [published correction in J Am Soc Nephrol. 2005;16:2814]. J Am Soc Nephrol. 2003; 14: 2573–2580.
19. Hostetter TH, Lising M. National kidney disease education program. J Am Soc Nephrol. 2003; 14: S114–S116.
20. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease [published comments in Ann Intern Med. 2004;141:959–961, Ann Intern Med. 2005;142:679–680; author reply 681]. Ann Intern Med. 2004; 141: 929–937.
21. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [published comment in J Am Coll Cardiol. 2002;39:1703–1704; author reply 1704–1705]. J Am Coll Cardiol. 2001; 38: 955–962.
22. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis [published comment in Diabetologia. 1989;32:766–767]. Diabetologia. 1989; 32: 219–226.[CrossRef][Medline] [Order article via Infotrieve]
23. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001; 103: 1869–1874.
24. American Diabetes Association. Standards of medical care in diabetes [published correction in Diabetes Care. 2005;28:990]. Diabetes Care. 2005; 28: S4–S36.
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [published correction in Ann Intern Med. 2003;139:605. Published comments in Ann Intern Med. 2003;139:I36, Ann Intern Med. 2004;140:933–934; author reply 934–935]. Ann Intern Med. 2003; 139: 137–147.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002; 39 (2 suppl 1): S1–S266.[CrossRef][Medline] [Order article via Infotrieve]
27. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43 (suppl 1): S1–S290.[Medline] [Order article via Infotrieve]
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [published comments in Hypertension. 2004;43:327; author reply e27; Hypertension. 2004;43:1–3; Hypertension. 2004;43:e31; author reply e31]. Hypertension. 2003; 42: 1206–1252.
This article has been cited by other articles:
 |
|
 |
|
  American College of Cardiology Foundation, American Heart Association Task Force on Practice, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine, Society for Vascular Surgery, L. A. Fleisher, et al. 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery J. Am. Coll. Cardiol., November 2, 2009; (2009) j.jacc.2009.07.010v1. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Buchman, D. Tanne, P. A. Boyle, R. C. Shah, S. E. Leurgans, and D. A. Bennett Kidney function is associated with the rate of cognitive decline in the elderly Neurology, September 22, 2009; 73(12): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bang, M. Mazumdar, G. Newman, A. S. Bomback, C. M. Ballantyne, A. S. Jaffe, P. A. August, and A. V. Kshirsagar Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2452 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Reinecke, E. Brand, R. Mesters, W.-R. Schabitz, M. Fisher, H. Pavenstadt, and G. Breithardt Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2009; 20(4): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yahalom, R. Schwartz, Y. Schwammenthal, O. Merzeliak, M. Toashi, D. Orion, B.-A. Sela, and D. Tanne Chronic Kidney Disease and Clinical Outcome in Patients With Acute Stroke Stroke, April 1, 2009; 40(4): 1296 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Abboud, J. Labreuche, C. Duyckaerts, J-J Hauw, and P. Amarenco Prevalence of nephroangiosclerosis in patients with fatal stroke Neurology, March 10, 2009; 72(10): 899 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ovbiagele Medications Impair Kidney Function in Stroke Population--Reply Arch Neurol, March 1, 2009; 66(3): 416 - 416. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cohen Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Mayo Clin. Proc., February 1, 2009; 84(2): 149 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goldfarb, P. A. McCullough, J. McDermott, and S. B. Gay Contrast-Induced Acute Kidney Injury: Specialty-Specific Protocols for Interventional Radiology, Diagnostic Computed Tomography Radiology, and Interventional Cardiology Mayo Clin. Proc., February 1, 2009; 84(2): 170 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ritz and A. Remppis CHAPTER 15b Cardiovascular Problems in Chronic Kidney Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Saran and T. D. DuBose Jr Cardiovascular disease in chronic kidney disease Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 425 - 434. [Abstract] [PDF]
|
|
|
|
|
|
C. Clajus, J. U. Becker, D. O. Stichtenoth, J. Wortmann, A. Schwarz, and J. T. Kielstein Reply Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2705 - 2705. [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd, J. J. P. Kastelein, V. A. Bittner, R. Carmena, P. C. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. L. Zuckerman, N. K. Wenger, et al. Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease Mayo Clin. Proc., August 1, 2008; 83(8): 870 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ovbiagele Impairment in Glomerular Filtration Rate or Glomerular Filtration Barrier and Occurrence of Stroke Arch Neurol, July 1, 2008; 65(7): 934 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meyer, H. Bunzemeier, M. Hausberg, M. Walter, N. Roeder, G. Breithardt, and H. Reinecke Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1955 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the TNT (Treating to New Targets) Investigator Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Amsalem, M. Garty, R. Schwartz, A. Sandach, S. Behar, A. Caspi, S. Gottlieb, D. Ezra, B. S. Lewis, and J. Leor Prevalence and significance of unrecognized renal insufficiency in patients with heart failure Eur. Heart J., April 2, 2008; 29(8): 1029 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Melloni, E. D. Peterson, A. Y. Chen, L. A. Szczech, L. K. Newby, R. A. Harrington, W. B. Gibler, E. M. Ohman, S. A. Spinler, M. T. Roe, et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol., March 11, 2008; 51(10): 991 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation, January 15, 2008; 117(2): 261 - 295. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yoshida, H. Tomiyama, J. Yamada, Y. Koji, K. Shiina, M. Nagata, and A. Yamashina Relationships among Renal Function Loss within the Normal to Mildly Impaired Range, Arterial Stiffness, Inflammation, and Oxidative Stress Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1118 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the Treating to New Targets Investigators Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery J. Am. Coll. Cardiol., October 23, 2007; 50(17): e159 - e242. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, J. R. Kersten, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Circulation, October 23, 2007; 116(17): e418 - e500. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kielstein, K. Sydow, and T. Thum Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock JAMA, September 5, 2007; 298(9): 971 - 971. [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Chonchol, V. Aboyans, P. Lacroix, G. Smits, T. Berl, and M. Laskar Long-term outcomes after coronary artery bypass grafting: Preoperative kidney function is prognostic J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 683 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Kielstein, A. Woywodt, and S. R. Salpeter Letter by Kielstein et al Regarding Article, "High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid" Circulation, May 8, 2007; 115(18): e450 - e451. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||